抄録
In summary, increased bone marrow MVD as well as plasma concentrations of angiogenic growth factors are correlated with disease activity in MM. These results suggest that bone marrow angiogenesis may be an important factor for disease progression and can also be a therapeutic target. Thalidomide, known as an inhibitor of angiogenesis, was effective for the treatment of refractory MM. However, special caution must be paid to it's adverse effects.
| 本文言語 | English |
|---|---|
| ページ（範囲） | 303-305 |
| ページ数 | 3 |
| ジャーナル | Internal Medicine |
| 巻 | 42 |
| 号 | 3 |
| DOI | |
| 出版ステータス | Published - 2003 3月 1 |
ASJC Scopus subject areas
- 内科学